TrialPercutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Trial details
- Registry ID
- NCT02678572
- Phase
- Phase 3
DCTH
Delcath Systems Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaNCT02678572 | DCTH | Phase 3 | Completed | 2023-05-18Actual |
| An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaNCT05022901 | DCTH | Phase 3 | Active not recruiting | 2024-03-01Estimated |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseaseNCT06607458 | DCTH | Phase 2 | Recruiting | 2026-12Estimated |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant DiseaseNCT06875128 | DCTH | Phase 2 | Recruiting | 2029-05Estimated |
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Trial details
- Registry ID
- NCT05022901
- Phase
- Phase 3
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
Trial details
- Registry ID
- NCT06607458
- Phase
- Phase 2
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Trial details
- Registry ID
- NCT06875128
- Phase
- Phase 2
Latest recorded trial changes
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
NCT02678572 · Delcath Systems Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Objective Response Rate (ORR) as determined by Independent Central Review Committee
+ After
Measure: Objective Response Rate (ORR) as Determined by Independent Central Review Committee.
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
NCT06875128 · Delcath Systems Inc.
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting